ValuEngine downgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a hold rating to a sell rating in a research note published on Friday morning, ValuEngine reports.

Several other research analysts have also recently commented on the company. Piper Jaffray Companies reaffirmed a buy rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research report on Monday, December 16th. BidaskClub cut Crispr Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 1st. Roth Capital raised their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Canaccord Genuity raised their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the company a positive rating in a research report on Wednesday, November 20th. Finally, William Blair raised Crispr Therapeutics from a market perform rating to an outperform rating in a research report on Tuesday, November 19th. Three analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the stock. Crispr Therapeutics has a consensus rating of Buy and an average target price of $71.38.

Shares of Crispr Therapeutics stock opened at $59.44 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The company has a market capitalization of $3.28 billion, a P/E ratio of -17.28 and a beta of 3.20. Crispr Therapeutics has a 1 year low of $28.95 and a 1 year high of $74.00. The business has a 50-day moving average of $65.98 and a two-hundred day moving average of $51.14.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. On average, equities analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $390,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 over the last ninety days. Company insiders own 21.40% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. NEXT Financial Group Inc increased its holdings in Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares in the last quarter. Coastal Investment Advisors Inc. purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth approximately $26,000. US Bancorp DE boosted its stake in shares of Crispr Therapeutics by 553.7% in the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares during the last quarter. BSW Wealth Partners purchased a new position in shares of Crispr Therapeutics in the 2nd quarter worth approximately $39,000. Finally, BNP Paribas Arbitrage SA purchased a new position in shares of Crispr Therapeutics in the 2nd quarter worth approximately $41,000. 49.82% of the stock is owned by hedge funds and other institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: What Are Cryptocurrencies?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link